Related references
Note: Only part of the references are listed.Repression of the stress granule protein G3BP2 inhibits immune checkpoint molecule PD-L1
Yanhong Zhang et al.
MOLECULAR ONCOLOGY (2022)
Identification of STXBP6-IRF1 positive feedback loop in regulation of PD-L1 in cancer
Yanbin Liu et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2021)
Peptide Blocking CTLA-4 and B7-1 Interaction
Stepan V. Podlesnykh et al.
MOLECULES (2021)
TFH cells depend on Tcf1-intrinsic HDAC activity to suppress CTLA4 and guard B-cell help function
Fengyin Li et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2021)
Inhibition of T-cell-mediated immune response via the PD-1/PD-L1 axis in cholangiocarcinoma cells
Tawit Suriyo et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2021)
Molecular characterization, biological function, tumor microenvironment association and clinical significance of m6A regulators in lung adenocarcinoma
Yin Li et al.
BRIEFINGS IN BIOINFORMATICS (2021)
Reducing PD-L1 expression with a self-assembled nanodrug: an alternative to PD-L1 antibody for enhanced chemo-immunotherapy
Shuxian Cai et al.
THERANOSTICS (2021)
PD-L1 expression is associated with ALK positivity and STAT3 activation, but not outcome in patients with systemic anaplastic large cell lymphoma
Jing Shen et al.
MODERN PATHOLOGY (2020)
IFI16 promotes cervical cancer progression by upregulating PD-L1 in immunomicroenvironment through STING-TBK1-NF-kB pathway
Hongning Cai et al.
BIOMEDICINE & PHARMACOTHERAPY (2020)
Cisplatin-mediated down-regulation of miR-145 contributes to up-regulation of PD-L1 via the c-Myc transcription factor in cisplatin-resistant ovarian carcinoma cells
Q. Sheng et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2020)
Enhanced histone H3 acetylation of the PD-L1 promoter via the COP1/c-Jun/HDAC3 axis is required for PD-L1 expression in drug-resistant cancer cells
Haifang Wang et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2020)
Interferon regulatory factor 1 (IRF-1) and IRF-2 regulate PD-L1 expression in hepatocellular carcinoma (HCC) cells
Yihe Yan et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2020)
The landscape of CD28, CD80, CD86, CTLA4, and ICOS DNA methylation in head and neck squamous cell carcinomas
Luka de Vos et al.
EPIGENETICS (2020)
Epigenetically silenced PD-L1 confers drug resistance to anti-PD1 therapy in gastric cardia adenocarcinoma
Tianyu Zhu et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2020)
Verteporfin Inhibits PD-L1 through Autophagy and the STAT1-IRF1-TRIM28 Signaling Axis, Exerting Antitumor Efficacy
Jiyong Liang et al.
CANCER IMMUNOLOGY RESEARCH (2020)
Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma The CheckMate 143 Phase 3 Randomized Clinical Trial
David A. Reardon et al.
JAMA ONCOLOGY (2020)
Ubiquitin C-terminal hydrolase L1 promotes expression of programmed cell death-ligand 1 in non-small-cell lung cancer cells
Rudi Mao et al.
CANCER SCIENCE (2020)
The multi-kinase inhibitor lenvatinib interacts with the HDAC inhibitor entinostat to kill liver cancer cells
Jane L. Roberts et al.
CELLULAR SIGNALLING (2020)
Angiotensin II contributes to intratumoral immunosuppression via induction of PD-L1 expression in non-small cell lung carcinoma
Kaiyong Yang et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2020)
IL-6 promotes PD-L1 expression in monocytes and macrophages by decreasing protein tyrosine phosphatase receptor type O expression in human hepatocellular carcinoma
Wenjie Zhang et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
NDAT Targets PI3K-Mediated PD-L1 Upregulation to Reduce Proliferation in Gefitinib-Resistant Colorectal Cancer
Tung-Yung Huang et al.
CELLS (2020)
CDK7 inhibitor THZ1 enhances antiPD-1 therapy efficacy via the p38α/MYC/PD-L1 signaling in non-small cell lung cancer
Jian Wang et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2020)
RNA N6-methyladenosine demethylase FTO regulates PD-L1 expression in colon cancer cells
Nobuhiro Tsuruta et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2020)
HDAC Inhibition Induces PD-L1 Expression in a Novel Anaplastic Thyroid Cancer Cell Line
Luca Hegedus et al.
PATHOLOGY & ONCOLOGY RESEARCH (2020)
Akt-targeted therapy as a promising strategy to overcome drug resistance in breast cancer – A comprehensive review from chemotherapy to immunotherapy
Parham Jabbarzadeh Kaboli et al.
PHARMACOLOGICAL RESEARCH (2020)
P53-regulated miR-320a targets PDL1 and is downregulated in malignant mesothelioma (vol 11, 748, 2020)
Caterina Costa et al.
CELL DEATH & DISEASE (2020)
Comprehensive Analysis of the PD-L1 and Immune Infiltrates of m6A RNA Methylation Regulators in Head and Neck Squamous Cell Carcinoma
Lilan Yi et al.
MOLECULAR THERAPY-NUCLEIC ACIDS (2020)
Up-regulation of circRNA-0003528 promotes mycobacterium tuberculosis associated macrophage polarization via down-regulating miR-224-5p, miR-324-5p and miR-488-5p and up-regulating CTLA4
Zikun Huang et al.
AGING-US (2020)
Regulation of PD-L1 Expression by NF-κB in Cancer
Fabrizio Antonangeli et al.
FRONTIERS IN IMMUNOLOGY (2020)
Beyond T-Cells: Functional Characterization of CTLA-4 Expression in Immune and Non-Immune Cell Types
Damilola Oyewole-Said et al.
FRONTIERS IN IMMUNOLOGY (2020)
Buparlisib modulates PD-L1 expression in head and neck squamous cell carcinoma cell lines
Mathias Fiedler et al.
EXPERIMENTAL CELL RESEARCH (2020)
Epstein-Barr virus-encoded EBNA2 alters immune checkpoint PD-L1 expression by downregulating miR-34a in B-cell lymphomas
Eleni Anastasiadou et al.
LEUKEMIA (2019)
MicroRNA-497-5p down-regulation increases PD-L1 expression in clear cell renal cell carcinoma
Fajun Qu et al.
JOURNAL OF DRUG TARGETING (2019)
Phase Ib study of atezolizumab combined with cobimetinib in patients with solid tumors
M. D. Hellmann et al.
ANNALS OF ONCOLOGY (2019)
Upregulation of PD-L1 via HMGB1-Activated IRF3 and NF-kB Contributes to UV Radiation-Induced Immune Suppression
Wei Wang et al.
CANCER RESEARCH (2019)
Glioblastoma-Derived IL6 Induces Immunosuppressive Peripheral Myeloid Cell PD-L1 and Promotes Tumor Growth
Jonathan B. Lamano et al.
CLINICAL CANCER RESEARCH (2019)
MET Inhibitors Promote Liver Tumor Evasion of the Immune Response by Stabilizing PDL1
Hui Li et al.
GASTROENTEROLOGY (2019)
Secreted PD-L1 variants mediate resistance to PD-L1 blockade therapy in non-small cell lung cancer
Bo Gong et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2019)
S100A9-induced overexpression of PD-1/PD-L1 contributes to ineffective hematopoiesis in myelodysplastic syndromes
Pinyang Cheng et al.
LEUKEMIA (2019)
miRNA-148a-3p Regulates Immunosuppression in DNA Mismatch Repair-Deficient Colorectal Cancer by Targeting PD-L1
Mai Ashizawa et al.
MOLECULAR CANCER RESEARCH (2019)
Anti-tumour immunity controlled through mRNA m6A methylation and YTHDF1 in dendritic cells
Dali Han et al.
NATURE (2019)
Reactive oxygen species modulate macrophage immunosuppressive phenotype through the up-regulation of PD-L1
Cecilia Roux et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
Increased Programmed Death-Ligand 1 is an Early Epithelial Cell Response to Helicobacter pylori Infection
Loryn Holokai et al.
PLOS PATHOGENS (2019)
Synergistic inhibition of pancreatic cancer with anti-PD-L1 and c-Myc inhibitor JQ1
Yu Pan et al.
ONCOIMMUNOLOGY (2019)
MiR-873/PD-L1 axis regulates the stemness of breast cancer cells
Lanlan Gao et al.
EBIOMEDICINE (2019)
PD-L1 Expression in Human Breast Cancer Stem Cells Is Epigenetically Regulated through Posttranslational Histone Modifications
Pramod Darvin et al.
JOURNAL OF ONCOLOGY (2019)
Inhibiting PD-L1 palmitoylation enhances T-cell immune responses against tumours
Han Yao et al.
NATURE BIOMEDICAL ENGINEERING (2019)
ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach
C. Luchini et al.
ANNALS OF ONCOLOGY (2019)
Suppression of Exosomal PD-L1 Induces Systemic Anti-tumor Immunity and Memory
Mauro Poggio et al.
CELL (2019)
Inhibition of ATM reverses EMT and decreases metastatic potential of cisplatin-resistant lung cancer cells through JAK/STAT3/PD-L1 pathway
Mingjing Shen et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2019)
MAPK pathway activity plays a key role in PD-L1 expression of lung adenocarcinoma cells
Thijs S. Stutvoet et al.
JOURNAL OF PATHOLOGY (2019)
Targeting DNA Methylation and EZH2 Activity to Overcome Melanoma Resistance to Immunotherapy
Abdullah Al Emran et al.
TRENDS IN IMMUNOLOGY (2019)
EZH2 regulates PD-L1 expression via HIF-1α in non-small cell lung cancer cells
Yuetao Zhao et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2019)
A tumor-targeting nanomedicine carrying the p53 gene crosses the blood-brain barrier and enhances anti-PD-1 immunotherapy in mouse models of glioblastoma
Sang-Soo Kim et al.
INTERNATIONAL JOURNAL OF CANCER (2019)
IL-6/JAK1 pathway drives PD-L1 Y112 phosphorylation to promote cancer immune evasion
Li-Chuan Chan et al.
JOURNAL OF CLINICAL INVESTIGATION (2019)
Combination of CTLA-4 and PD-1 blockers for treatment of cancer
Anand Rotte
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2019)
IRF1 Inhibits Antitumor Immunity through the Upregulation of PD-L1 in the Tumor Cell
Lulu Shao et al.
CANCER IMMUNOLOGY RESEARCH (2019)
MET Receptor Tyrosine Kinase Regulates the Expression of Co-Stimulatory and Co-Inhibitory Molecules in Tumor Cells and Contributes to PD-L1-Mediated Suppression of Immune Cell Function
Hyun Kyung Ahn et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
IFN-gamma-induced PD-L1 expression in melanoma depends on p53 expression
Alexander Thiem et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2019)
Immune checkpoint inhibitors of PD-L1 as cancer therapeutics
Akintunde Akinleye et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)
Heterogeneity-of PD-L1 expression in non-small cell lung cancer: Implications for specimen sampling in predicting treatment response
Alexander Haragan et al.
LUNG CANCER (2019)
USP22 Deubiquitinates CD274 to Suppress Anticancer Immunity
Xing Huang et al.
CANCER IMMUNOLOGY RESEARCH (2019)
Small-Molecule MYC Inhibitors Suppress Tumor Growth and Enhance Immunotherapy
Huiying Han et al.
CANCER CELL (2019)
Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4
Shuang Qin et al.
MOLECULAR CANCER (2019)
Role of hypoxia in cancer therapy by regulating the tumor microenvironment
Xinming Jing et al.
MOLECULAR CANCER (2019)
EGFR-TKI resistance promotes immune escape in lung cancer via increased PD-L1 expression
Shunli Peng et al.
MOLECULAR CANCER (2019)
Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic
T. A. Chan et al.
ANNALS OF ONCOLOGY (2019)
EZH2 negatively regulates PD-L1 expression in hepatocellular carcinoma
Gang Xiao et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Enhanced anti-tumor efficacy of checkpoint inhibitors in combination with the histone deacetylase inhibitor Belinostat in a murine hepatocellular carcinoma model
Diana Llopiz et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2019)
Palmitoylation stabilizes PD-L1 to promote breast tumor growth
Yi Yang et al.
CELL RESEARCH (2019)
MiR-214 prevents the progression of diffuse large B-cell lymphoma by targeting PD-L1
Jing-Ran Sun et al.
CELLULAR & MOLECULAR BIOLOGY LETTERS (2019)
Functional loss of ARID1A is tightly associated with high PD-L1 expression in gastric cancer
Young-Bae Kim et al.
INTERNATIONAL JOURNAL OF CANCER (2019)
Phosphorylated RB Promotes Cancer Immunity by Inhibiting NF-κB Activation and PD-L1 Expression
Xin Jin et al.
MOLECULAR CELL (2019)
PD-L1 methylation regulates PD-L1 expression and is associated with melanoma survival
Goran Micevic et al.
PIGMENT CELL & MELANOMA RESEARCH (2019)
JAK-STAT Signaling: A Double-Edged Sword of Immune Regulation and Cancer Progression
Katie L. Owen et al.
CANCERS (2019)
Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression (vol 19, pg 1189, 2017)
Angel Garcia-Diaz et al.
CELL REPORTS (2019)
Genomic analyses of flow-sorted Hodgkin Reed-Sternberg cells reveal complementary mechanisms of immune evasion
Kirsty Wienand et al.
BLOOD ADVANCES (2019)
Cyclin D-CDK4 kinase destabilizes PD-L1 via cullin 3-SPOP to control cancer immune surveillance
Jinfang Zhang et al.
NATURE (2018)
PD-L1 (CD274) and PD-L2 (PDCD1LG2) promoter methylation is associated with HPV infection and transcriptional repression in head and neck squamous cell carcinomas
Alina Franzen et al.
ONCOTARGET (2018)
Analysis of PD1, PDL1, PDL2 expression and T cells infiltration in 1014 gastric cancer patients
Xiaofang Xing et al.
ONCOIMMUNOLOGY (2018)
Interactions between EGFR and PD-1/PD-L1 pathway: Implications for treatment of NSCLC
Xue Li et al.
CANCER LETTERS (2018)
Combined Blockade of IL6 and PD-1/PD-L1 Signaling Abrogates Mutual Regulation of Their Immunosuppressive Effects in the Tumor Microenvironment
Hirotake Tsukamoto et al.
CANCER RESEARCH (2018)
Exosomal PD-L1 harbors active defense function to suppress T cell killing of breast cancer cells and promote tumor growth
Yi Yang et al.
CELL RESEARCH (2018)
IDO1 in cancer: a Gemini of immune checkpoints
Lijie Zhai et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2018)
MiR-140 Expression Regulates Cell Proliferation and Targets PD-L1 in NSCLC
Wei-Bin Xie et al.
CELLULAR PHYSIOLOGY AND BIOCHEMISTRY (2018)
JAK2 and PD-L1 Amplification Enhance the Dynamic Expression of PD-L1 in Triple-negative Breast Cancer
Meixuan Chen et al.
CLINICAL BREAST CANCER (2018)
Soluble Programmed Cell Death Ligand 1 as a Novel Biomarker for Nivolumab Therapy for Non-Small-cell Lung Cancer
Yusuke Okuma et al.
CLINICAL LUNG CANCER (2018)
E3 ubiquitin ligases Cbl-b and c-Cbl downregulate PD-L1 in EGFR wild-type non-small cell lung cancer
Shuo Wang et al.
FEBS LETTERS (2018)
PTEN/PTENP1: 'Regulating the regulator of RTK-dependent PI3K/Akt signalling', new targets for cancer therapy
Nahal Haddadi et al.
MOLECULAR CANCER (2018)
A HER2-Targeting Antibody-Drug Conjugate, Trastuzumab Deruxtecan (DS-8201a), Enhances Antitumor Immunity in a Mouse Model
Tomomi Nakayama Iwata et al.
MOLECULAR CANCER THERAPEUTICS (2018)
MYC inhibition increases PD-L1 expression induced by IFN-γ in hepatocellular carcinoma cells
Jiahuan Zou et al.
MOLECULAR IMMUNOLOGY (2018)
Inhibition of IL-6-JAK/Stat3 signaling in castration-resistant prostate cancer cells enhances the NK cell-mediated cytotoxicity via alteration of PD-L1/NKG2D ligand levels
Lijun Xu et al.
MOLECULAR ONCOLOGY (2018)
Control of PD-L1 expression by miR-140/142/340/383 and oncogenic activation of the OCT4-miR-18a pathway in cervical cancer
Peixin Dong et al.
ONCOGENE (2018)
Genetic, transcriptional and post-translational regulation of the programmed death protein ligand 1 in cancer: biology and clinical correlations
Ioannis Zerdes et al.
ONCOGENE (2018)
Cancer-associated fibroblasts induce PDL1+neutrophils through the IL6-STAT3 pathway that foster immune suppression in hepatocellular carcinoma
Yusheng Cheng et al.
CELL DEATH & DISEASE (2018)
STT3-dependent PD-L1 accumulation on cancer stem cells promotes immune evasion
Jung-Mao Hsu et al.
NATURE COMMUNICATIONS (2018)
Correlation of MET gene amplification and TP53 mutation with PD-L1 expression in non-small cell lung cancer
Maher Albitar et al.
Oncotarget (2018)
Deubiquitination and stabilization of programmed cell death ligand 1 by ubiquitin-specific peptidase 9, X-linked in oral squamous cell carcinoma
Wu Jingjing et al.
CANCER MEDICINE (2018)
PD-L1 expression is regulated by both DNA methylation and NF-kappa B during EMT signaling in non-small cell lung carcinoma
A. Asgarova et al.
ONCOIMMUNOLOGY (2018)
Prevalence of PDL1 Amplification and Preliminary Response to Immune Checkpoint Blockade in Solid Tumors
Aaron M. Goodman et al.
JAMA ONCOLOGY (2018)
Current landscape and future of dual anti-CTLA4 and PD-1/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung cancer (NSCLC)
Young Kwang Chae et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations
Jun Gong et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Oncogenic activation of the STAT3 pathway drives PD-L1 expression in natural killer/T-cell lymphoma
Tammy Linlin Song et al.
BLOOD (2018)
The Protein Expression of PDL1 Is Highly Correlated with Those of eIF2α and ATF4 in Lung Cancer
Liang-Che Chang et al.
DISEASE MARKERS (2018)
Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors
Ming Yi et al.
MOLECULAR CANCER (2018)
Metformin Promotes Antitumor Immunity via Endoplasmic-Reticulum-Associated Degradation of PD-L1
Jong-Ho Cha et al.
MOLECULAR CELL (2018)
Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response
Gang Chen et al.
NATURE (2018)
Histone Deacetylase Inhibitors in Cancer Therapy
Yijie Sun et al.
CURRENT TOPICS IN MEDICINAL CHEMISTRY (2018)
BRD4 and Cancer: going beyond transcriptional regulation
Benedetta Donati et al.
MOLECULAR CANCER (2018)
Hedgehog signaling induces PD-L1 expression and tumor cell proliferation in gastric cancer
Jayati Chakrabarti et al.
Oncotarget (2018)
Known and novel roles of the MET oncogene in cancer: a coherent approach to targeted therapy
Paolo M. Comoglio et al.
NATURE REVIEWS CANCER (2018)
Clinical Significance of PD-L1+ Exosomes in Plasma of Head and Neck Cancer Patients
Marie-Nicole Theodoraki et al.
CLINICAL CANCER RESEARCH (2018)
Is H3K4me3 instructive for transcription activation
Francoise S. Howe et al.
BIOESSAYS (2017)
Genomic Amplification of CD274 (PD-L1) in Small-Cell Lung Cancer
Julie George et al.
CLINICAL CANCER RESEARCH (2017)
Myeloid cells are required for PD-1/PD-L1 checkpoint activation and the establishment of an immunosuppressive environment in pancreatic cancer
Yaqing Zhang et al.
GUT (2017)
PD-L1 (CD274) promoter methylation predicts survival in colorectal cancer patients
Diane Goltz et al.
ONCOIMMUNOLOGY (2017)
Mutant p53 as a target for cancer treatment
Michael J. Duffy et al.
EUROPEAN JOURNAL OF CANCER (2017)
Oncogenic RAS Signaling Promotes Tumor Immunoresistance by Stabilizing PD-L1 mRNA
Matthew A. Coelho et al.
IMMUNITY (2017)
Oral squamous cell carcinoma suppressed antitumor immunity through induction of PD-Ll expression on tumor-associated macrophages
Canhua Jiang et al.
IMMUNOBIOLOGY (2017)
Inflammatory cytokines IL-17 and TNF-α up-regulate PD-L1 expression in human prostate and colon cancer cells
Xun Wang et al.
IMMUNOLOGY LETTERS (2017)
MicroRNA-155 induction via TNF- and IFN- suppresses expression of programmed death ligand-1 (PD-L1) in human primary cells
Daniel Yee et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2017)
Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma
Austin G. Duffy et al.
JOURNAL OF HEPATOLOGY (2017)
The MLL1-H3K4me3 Axis-Mediated PD-L1 Expression and Pancreatic Cancer Immune Evasion
Chunwan Lu et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2017)
Tumor Suppressor microRNAs Contribute to the Regulation of PD-L1 Expression in Malignant Pleural Mesothelioma
Steven C. Kao et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)
Jacob Schachter et al.
LANCET (2017)
PD-L1 is commonly expressed and transcriptionally regulated by STAT3 and MYC in ALK-negative anaplastic large-cell lymphoma
V. Atsaves et al.
LEUKEMIA (2017)
MYC expression correlates with PD-L1 expression in non-small cell lung cancer
Eun Young Kim et al.
LUNG CANCER (2017)
High plasma levels of soluble programmed cell death ligand 1 are prognostic for reduced survival in advanced lung cancer
Yusuke Okuma et al.
LUNG CANCER (2017)
Identification of CMTM6 and CMTM4 as PD-L1 protein regulators
Riccardo Mezzadra et al.
NATURE (2017)
CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity
Marian L. Burr et al.
NATURE (2017)
BIN1 reverses PD-L1-mediated immune escape by inactivating the c-MYC and EGFR/MAPK signaling pathways in non-small cell lung cancer
J. Wang et al.
ONCOGENE (2017)
MUC1-C integrates PD-L1 induction with repression of immune effectors in non-small-cell lung cancer
A. Bouillez et al.
ONCOGENE (2017)
Helicobacter Pylori Promote B7-H1 Expression by Suppressing miR-152 and miR-200b in Gastric Cancer Cells
Gengchen Xie et al.
PLOS ONE (2017)
DNA double-strand break repair pathway regulates PD-L1 expression in cancer cells
Hiro Sato et al.
NATURE COMMUNICATIONS (2017)
Radiation alters PD-L1/NKG2D ligand levels in lung cancer cells and leads to immune escape from NK cell cytotoxicity via IL-6-MEK/Erk signaling pathway
Ming Jing Shen et al.
ONCOTARGET (2017)
EGFR or HER2 inhibition modulates the tumor microenvironment by suppression of PD-L1 and cytokines release
Koung Jin Suh et al.
ONCOTARGET (2017)
A regulatory role for the co-chaperone FKBP51s in PD-L1 expression in glioma
Paolo D'Arrigo et al.
Oncotarget (2017)
The miR-25-93-106b cluster regulates tumor metastasis and immune evasion via modulation of CXCL12 and PD-L1
Michele Cioffi et al.
ONCOTARGET (2017)
miR-217 inhibits laryngeal cancer metastasis by repressing AEG-1 and PD-L1 expression
Susheng Miao et al.
ONCOTARGET (2017)
PD-L1 up-regulation in melanoma increases disease aggressiveness and is mediated through miR-17-5p
Valentina Audrito et al.
ONCOTARGET (2017)
HDAC inhibitors enhance neratinib activity and when combined enhance the actions of an anti-PD-1 immunomodulatory antibody in vivo
Laurence Booth et al.
ONCOTARGET (2017)
HDAC inhibition potentiates immunotherapy in triple negative breast cancer
Manuela Terranova-Barberio et al.
ONCOTARGET (2017)
HDAC inhibitors enhance the immunotherapy response of melanoma cells
Laurence Booth et al.
ONCOTARGET (2017)
BET-Bromodomain Inhibitors Engage the Host Immune System and Regulate Expression of the Immune Checkpoint Ligand PD-L1
Simon J. Hogg et al.
CELL REPORTS (2017)
Epigenetic modifications of the immune-checkpoint genes CTLA4 and PDCD1 in non-small cell lung cancer results in increased expression
Sebastian Marwitz et al.
CLINICAL EPIGENETICS (2017)
The MLL1-H3K4me3 Axis-Mediated PD-L1 Expression and Pancreatic Cancer Immune Evasion
Chunwan Lu et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2017)
Temporally Distinct PD-L1 Expression by Tumor and Host Cells Contributes to Immune Escape
Takuro Noguchi et al.
CANCER IMMUNOLOGY RESEARCH (2017)
Soluble PD-L1 as a Biomarker in Malignant Melanoma Treated with Checkpoint Blockade
Jun Zhou et al.
CANCER IMMUNOLOGY RESEARCH (2017)
A novel bifunctional anti-PD-L1/TGF-β Trap fusion protein (M7824) efficiently reverts mesenchymalization of human lung cancer cells
Justin M. David et al.
ONCOIMMUNOLOGY (2017)
Basal cell carcinoma: PD-L1/PD-1 checkpoint expression and tumor regression after PD-1 blockade
Evan J. Lipson et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2017)
[pemetrexed plus sildenafil], via autophagy-dependent HDAC downregulation, enhances the immunotherapy response of NSCLC cells
Laurence Booth et al.
CANCER BIOLOGY & THERAPY (2017)
Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review
L. Khoja et al.
ANNALS OF ONCOLOGY (2017)
PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression
Shiping Jiao et al.
CLINICAL CANCER RESEARCH (2017)
Therapeutic effect of a novel histone deacetylase 6 inhibitor, CKD-L, on collageninduced arthritis in vivo and regulatory T cells in rheumatoid arthritis in vitro
Bo Ram Oh et al.
ARTHRITIS RESEARCH & THERAPY (2017)
miR-142-5p regulates tumor cell PD-Ll expression and enhances anti-tumor immunity
Long Jia et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2017)
Control of PD-L1 Expression by Oncogenic Activation of the AKT-mTOR Pathway in Non-Small Cell Lung Cancer
Kristin J. Lastwika et al.
CANCER RESEARCH (2016)
RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors
Sherene Loi et al.
CLINICAL CANCER RESEARCH (2016)
PDL1 Regulation by p53 via miR-34
Maria Angelica Cortez et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2016)
PDL1 Regulation by p53 via miR-34
Maria Angelica Cortez et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2016)
EML4-ALK enhances programmed cell death-ligand 1 expression in pulmonary adenocarcinoma via hypoxia-inducible factor (HIF)-1 alpha and STAT3
Jaemoon Koh et al.
ONCOIMMUNOLOGY (2016)
CTLA-4 and PD-1 Pathways Similarities, Differences, and Implications of Their Inhibition
Elizabeth I. Buchbinder et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2016)
Deubiquitination and Stabilization of PD-L1 by CSN5
Seung-Oe Lim et al.
CANCER CELL (2016)
EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis
Justin F. Gainor et al.
CLINICAL CANCER RESEARCH (2016)
Renal Cell Carcinoma Programmed Death-ligand 1, a New Direct Target of Hypoxia-inducible Factor-2 Alpha, is Regulated by von Hippel-Lindau Gene Mutation Status
Yosra Messai et al.
EUROPEAN UROLOGY (2016)
PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome
Margaretha G. M. Roemer et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
PD-L1 is upregulated by EBV-driven LMP1 through NF-κB pathway and correlates with poor prognosis in natural killer/T-cell lymphoma
Xi-wen Bi et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2016)
PD-L1 Is Upregulated by Simultaneous Amplification of the PD-L1 and JAK2 Genes in Non-Small Cell Lung Cancer
Seiichi Ikeda et al.
JOURNAL OF THORACIC ONCOLOGY (2016)
Essential role of HDAC6 in the regulation of PD-L1 in melanoma
M. Lienlaf et al.
MOLECULAR ONCOLOGY (2016)
Aberrant PD-L1 expression through 3′-UTR disruption in multiple cancers
Keisuke Kataoka et al.
NATURE (2016)
Epigenetic Modulators and the New Immunotherapies
Anthony E. Dear
NEW ENGLAND JOURNAL OF MEDICINE (2016)
MYC regulates the antitumor immune response through CD47 and PD-L1
Stephanie C. Casey et al.
SCIENCE (2016)
Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity
Chia-Wei Li et al.
NATURE COMMUNICATIONS (2016)
miR-424(322) reverses chemoresistance via T-cell immune response activation by blocking the PD-L1 immune checkpoint
Shaohua Xu et al.
NATURE COMMUNICATIONS (2016)
The tumor suppressor miR-138-5p targets PD-L1 in colorectal cancer
Lian Zhao et al.
ONCOTARGET (2016)
CD274/PD-L1 gene amplification and PD-L1 protein expression are common events in squamous cell carcinoma of the oral cavity
Melanie Straub et al.
ONCOTARGET (2016)
BET Bromodomain Inhibition Promotes Anti-tumor Immunity by Suppressing PD-L1 Expression
Hengrui Zhu et al.
CELL REPORTS (2016)
TGFβ-dependent expression of PD-1 and PD-L1 controls CD8+ T cell anergy in transplant tolerance
Marije Baas et al.
ELIFE (2016)
The PD1:PD-L1/2 Pathway from Discovery to Clinical implementation
Kankana Bardhan et al.
FRONTIERS IN IMMUNOLOGY (2016)
RAS-Mitogen-Activated Protein Kinase Signal Is Required for Enhanced PD-L1 Expression in Human Lung Cancers
Hidetoshi Sumimoto et al.
PLOS ONE (2016)
TLR3 triggering regulates PD-L1 (CD274) expression in human neuroblastoma cells
Marianne Boes et al.
CANCER LETTERS (2015)
Tumor suppressor miR-34a targets PD-L1 and functions as a potential immunotherapeutic target in acute myeloid leukemia
Xi Wang et al.
CELLULAR SIGNALLING (2015)
Induction of PD-L1 Expression by the EML4-ALK Oncoprotein and Downstream Signaling Pathways in Non-Small Cell Lung Cancer
Keiichi Ota et al.
CLINICAL CANCER RESEARCH (2015)
The Clinical Relevance of the miR-197/CKS1B/STAT3-mediated PD-L1 Network in Chemoresistant Non-small-cell Lung Cancer
Yu Fujita et al.
MOLECULAR THERAPY (2015)
Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy
Dongjun Peng et al.
NATURE (2015)
Patients with LRBA deficiency show CTLA4 loss and immune dysregulation responsive to abatacept therapy
Bernice Lo et al.
SCIENCE (2015)
Temporal regulation of HIF-1 and NF-κB in hypoxic hepatocarcinoma cells
Yuan Jiang et al.
ONCOTARGET (2015)
IL-27 induces the expression of IDO and PD-L1 in human cancer cells
Grazia Carbotti et al.
ONCOTARGET (2015)
Inducible but Not Constitutive Expression of PD-L1 in Human Melanoma Cells Is Dependent on Activation of NF-κB
Kavitha Gowrishankar et al.
PLOS ONE (2015)
IL-12 Regulates B7-H1 Expression in Ovarian Cancerassociated Macrophages by Effects on NF-χB Signalling
Hai-Yu Xiong et al.
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION (2014)
Genomic rearrangements involving programmed death ligands are recurrent in primary mediastinal large B-cell lymphoma
David D. W. Twa et al.
BLOOD (2014)
Loss of Lkb1 and Pten Leads to Lung Squamous Cell Carcinoma with Elevated PD-L1 Expression
Chunxiao Xu et al.
CANCER CELL (2014)
A Mechanism of Hypoxia-Mediated Escape from Adaptive Immunity in Cancer Cells
Ivraym B. Barsoum et al.
CANCER RESEARCH (2014)
Inhibition of mitogen-activated protein kinase pathway can induce upregulation of human leukocyte antigen class I without PD-L1-upregulation in contrast to interferon-γ treatment
Kousaku Mimura et al.
CANCER SCIENCE (2014)
Effects of MAPK and PI3K Pathways on PD-L1 Expression in Melanoma
Mohammad Atefi et al.
CLINICAL CANCER RESEARCH (2014)
MiR-20b,-21, and-130b inhibit PTEN expression resulting in B7-H1 over-expression in advanced colorectal cancer
Jianjie Zhu et al.
HUMAN IMMUNOLOGY (2014)
PD-L1 is a novel direct target of HIF-1α., and its blockade under hypoxia enhanced MDSC-mediated T cell activation
Muhammad Zaeem Noman et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2014)
Synergistic effects of IL-4 and TNFα on the induction of B7-H1 in renal cell carcinoma cells inhibiting allogeneic T cell proliferation
Dagmar Quandt et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2014)
Rab8 Binding to Immune Cell-Specific Adaptor LAX Facilitates Formation of trans-Golgi Network-Proximal CTLA-4 Vesicles for Surface Expression
Matthew C. Banton et al.
MOLECULAR AND CELLULAR BIOLOGY (2014)
Comprehensive molecular characterization of gastric adenocarcinoma
Adam J. Bass et al.
NATURE (2014)
Protein kinase C-η controls CTLA-4-mediated regulatory T cell function
Kok-Fai Kong et al.
NATURE IMMUNOLOGY (2014)
MUC1-C oncoprotein activates the ZEB1/miR-200c regulatory loop and epithelial-mesenchymal transition
H. Rajabi et al.
ONCOGENE (2014)
MicroRNAs in cancer: biomarkers, functions and therapy
Josie Hayes et al.
TRENDS IN MOLECULAR MEDICINE (2014)
Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression
Limo Chen et al.
NATURE COMMUNICATIONS (2014)
Immune regulation by low doses of the DNA methyltransferase inhibitor 5-azacitidine in common human epithelial cancers
Huili Li et al.
ONCOTARGET (2014)
PD-L1 Expression in Triple-Negative Breast Cancer
Elizabeth A. Mittendorf et al.
CANCER IMMUNOLOGY RESEARCH (2014)
The Activation of MAPK in Melanoma Cells Resistant to BRAF Inhibition Promotes PD-L1 Expression That Is Reversible by MEK and PI3K Inhibition
Xiaofeng Jiang et al.
CLINICAL CANCER RESEARCH (2013)
PD-L1 Expression Is Characteristic of a Subset of Aggressive B-cell Lymphomas and Virus-Associated Malignancies
Benjamin J. Chen et al.
CLINICAL CANCER RESEARCH (2013)
Post-transcriptional control of candidate risk genes for type 1 diabetes by rare genetic variants
V. M. de Jong et al.
GENES AND IMMUNITY (2013)
A miR-570 binding site polymorphism in the B7-H1 gene is associated with the risk of gastric adenocarcinoma
Weipeng Wang et al.
HUMAN GENETICS (2013)
ALK in Lung Cancer: Past, Present, and Future
Alice T. Shaw et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
The complexity of NF-κB signaling in inflammation and cancer
Bastian Hoesel et al.
MOLECULAR CANCER (2013)
PTEN Loss Increases PD-L1 Protein Expression and Affects the Correlation between PD-L1 Expression and Clinical Parameters in Colorectal Cancer
Minmin Song et al.
PLOS ONE (2013)
Role of CTLA4 in the Proliferation and Survival of Chronic Lymphocytic Leukemia
Amit K. Mittal et al.
PLOS ONE (2013)
Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors
Esra A. Akbay et al.
CANCER DISCOVERY (2013)
SAHA, an HDAC inhibitor, synergizes with tacrolimus to prevent murine cardiac allograft rejection
Xin Zhang et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2012)
Constitutive AP-1 Activity and EBV Infection Induce PD-L1 in Hodgkin Lymphomas and Posttransplant Lymphoproliferative Disorders: Implications for Targeted Therapy
Michael R. Green et al.
CLINICAL CANCER RESEARCH (2012)
A multiply redundant genetic switch 'locks in' the transcriptional signature of regulatory T cells
Wenxian Fu et al.
NATURE IMMUNOLOGY (2012)
Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer
Julie R. Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
TGF-β of lung cancer microenvironment upregulates B7H1 and GITRL expression in dendritic cells and is associated with regulatory T cell generation
Xiao Yan Ni et al.
ONCOLOGY REPORTS (2012)
TNF-α and TGF-β Counter-Regulate PD-L1 Expression on Monocytes in Systemic Lupus Erythematosus
Jing-Ni Ou et al.
SCIENTIFIC REPORTS (2012)
Interleukin-17-educated monocytes suppress cytotoxic T-cell function through B7-H1 in hepatocellular carcinoma patients
Qiyi Zhao et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2011)
ERK/p38 MAP-kinases and PI3K are involved in the differential regulation of B7-H1 expression in DC subsets
Svetlana Karakhanova et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2010)
MiR-155 is overexpressed in patients with atopic dermatitis and modulates T-cell proliferative responses by targeting cytotoxic T lymphocyte-associated antigen 4
Eniko Sonkoly et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2010)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
B7-H1 expression is regulated by MEK/ERK signaling pathway in anaplastic large cell lymphoma and Hodgkin lymphoma
Ryo Yamamoto et al.
CANCER SCIENCE (2009)
MicroRNA-513 Regulates B7-H1 Translation and Is Involved in IFN-γ-Induced B7-H1 Expression in Cholangiocytes
Ai-Yu Gong et al.
JOURNAL OF IMMUNOLOGY (2009)
Signal integration by JNK and p38 MAPK pathways in cancer development
Erwin F. Wagner et al.
NATURE REVIEWS CANCER (2009)
TLR4 signaling induces B7-H1 expression through MAPK pathways in bladder cancer cells
Yigang Qian et al.
CANCER INVESTIGATION (2008)
LPS/TLR4 signal transduction pathway
Yong-Chen Lu et al.
CYTOKINE (2008)
Drug therapy: EGFR antagonists in cancer treatment
Fortunato Ciardiello et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1)
Michal Marzec et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Induction of the CTLA-4 gene in human lymphocytes is dependent on NFAT binding the proximal promoter
Heather M. Gibson et al.
JOURNAL OF IMMUNOLOGY (2007)
Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-γ and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway
Jizhong Liu et al.
BLOOD (2007)
Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma
Andrew T. Parsa et al.
NATURE MEDICINE (2007)
TGF-Beta treatment modulates PD-L1 and CD40 expression in proximal renal tubular epithelial cells and enhances CD8(+) cytotoxic T-Cell responses
Astrid Starke et al.
NEPHRON EXPERIMENTAL NEPHROLOGY (2007)
T cell receptor-interacting molecule acts as a chaperone to modulate surface expression of the CTLA-4 coreceptor
Elke Valk et al.
IMMUNITY (2006)
FOXP3 controls regulatory T cell function through cooperation with NFAT
Yongqing Wu et al.
CELL (2006)
CTLA-4 interacts with STAT5 and inhibits STAT5-mediated transcription
M Srahna et al.
IMMUNOLOGY (2006)
Interferon regulatory factor-1 is prerequisite to the constitutive expression and IFN-γ-induced upregulation of B7-H1 (CD274)
SJ Lee et al.
FEBS LETTERS (2006)
Mechanisms of type-I- and type-II-interferon-mediated signalling
LC Platanias
NATURE REVIEWS IMMUNOLOGY (2005)
Exocytosis of CTLA-4 is dependent on phospholipase D and ADP ribosylation factor-1 and stimulated during activation of regulatory T cells
KI Mead et al.
JOURNAL OF IMMUNOLOGY (2005)
Hypoxia-induced neutrophil survival is mediated by HIF-1α-dependent NF-κB activity
SR Walmsley et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2005)
Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity
TJ Curiel et al.
NATURE MEDICINE (2003)
CTLA-4: new insights into its biological function and use in tumor immunotherapy
JG Egen et al.
NATURE IMMUNOLOGY (2002)
AP-1 as a regulator of cell life and death
E Shaulian et al.
NATURE CELL BIOLOGY (2002)
Share Paper
